AVXS-101 (Onasemnogene Abeparvovec) for SMA 1: Comparative Study with a Prospective Natural History Cohort

被引：139

作者：

Al-Zaidy, Samiah A. ^{[1
,2
]}

Kolb, Stephen J. ^{[3
,4
]}

Lowes, Linda ^{[1
,2
]}

Alfano, Lindsay N. ^{[1
,2
]}

Shell, Richard ^{[2
]}

Church, Kathleen R. ^{[1
]}

Nagendran, Sukumar ^{[5
]}

Sproule, Douglas M. ^{[5
]}

Feltner, Douglas E. ^{[5
]}

Wells, Courtney ^{[5
]}

Ogrinc, Francis ^{[5
]}

Menier, Melissa ^{[5
]}

L'Italien, James ^{[5
]}

Arnold, W. David ^{[3
]}

Kissel, John T. ^{[2
]}

Kaspar, Brian K. ^{[5
]}

Mendell, Jerry R. ^{[1
,2
,3
]}

机构：

[1] Nationwide Childrens Hosp, Ctr Gene Therapy Res Inst, Columbus, OH 43205 USA

[2] Ohio State Univ, Dept Pediat, Wexner Med Ctr, Columbus, OH 43210 USA

[3] Ohio State Univ, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA

[4] Ohio State Univ, Dept Biol Chem & Pharmacol, Wexner Med Ctr, Columbus, OH 43210 USA

[5] AveXis Inc, Bannockburn, IL USA

来源：

JOURNAL OF NEUROMUSCULAR DISEASES | 2019年 / 6卷 / 03期

关键词：

Gene therapy; spinal muscular atrophy; natural history; neuromuscular diseases;

D O I：

10.3233/JND-190403

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

Background: Spinal muscular atrophy type 1 (SMA1) is the leading genetic cause of infant mortality for which therapies, including AVXS-101 (onasemnogene abeparvovec, Zolgensma (R)) gene replacement therapy, are emerging. Objective: This study evaluated the effectiveness of AVXS-101 in infants with spinal muscular atrophy type 1 (SMA1) compared with a prospective natural history cohort and a cohort of healthy infants. Methods: Twelve SMA1 infants received the proposed therapeutic dose of AVXS-101 (NCT02122952). Where possible, the following outcomes were compared with a natural history cohort of SMA1 infants (n = 16) and healthy infants (n = 27) enrolled in the NeuroNEXT (NN101) study (NCT01736553): event-free survival, CHOP-INTEND scores, motor milestone achievements, compound muscle action potential (CMAP), and adverse events. Results: Baseline characteristics of SMA1 infants in the AVXS-101 and NN101 studies were similar in age and genetic profile. The proportion of AVXS-101-treated infants who survived by 24 months of follow-up was higher compared with the NN101 study (100% vs 38%, respectively). The average baseline CHOP-INTEND score for NN101 SMA1 infants was 20.3, worsening to 5.3 by age 24 months; the average baseline score in AVXS-101-treated infants was 28.2, improving to 56.5 by age 24 months. Infants receiving AVXS-101 achieved motor milestones, such as sitting unassisted and walking. Improvements in CMAP peak area were observed in AVXS-101-treated infants at 6 and 24 months (means of 1.1 and 3.2 mV/s, respectively). Conclusions: In this study, AVXS-101 increased the probability of survival, rapidly improved motor function, and enabled motor milestone achievement in SMA1 infants.

引用

页码：307 / 317

页数：11

共 22 条

[11]

Glascock Jacqueline, 2018, J Neuromuscul Dis, V5, P145, DOI 10.3233/JND-180304

[12]

Natural history of infantile-onset spinal muscular atrophy [J].

Kolb, Stephen J. ;

Coffey, Christopher S. ;

Yankey, Jon W. ;

Krosschell, Kristin ;

Arnold, W. David ;

Rutkove, Seward B. ;

Swoboda, Kathryn J. ;

Reyna, Sandra P. ;

Sakonju, Ai ;

Darras, Basil T. ;

Shell, Richard ;

Kuntz, Nancy ;

Castro, Diana ;

Parsons, Julie ;

Connolly, Anne M. ;

Chiriboga, Claudia A. ;

McDonald, Craig ;

Burnette, W. Bryan ;

Werner, Klaus ;

Thangarajh, Mathula ;

Shieh, Perry B. ;

Finanger, Erika ;

Cudkowicz, Merit E. ;

McGovern, Michelle M. ;

McNeil, D. Elizabeth ;

Finkel, Richard ;

Iannaccone, Susan T. ;

Kaye, Edward ;

Kingsley, Allison ;

Renusch, Samantha R. ;

McGovern, Vicki L. ;

Wang, Xueqian ;

Zaworski, Phillip G. ;

Prior, Thomas W. ;

Burghes, Arthur H. M. ;

Bartlett, Amy ;

Kissel, John T. .

ANNALS OF NEUROLOGY, 2017, 82 (06) :883-891

[13]

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study [J].

Kolb, Stephen J. ;

Coffey, Christopher S. ;

Yankey, Jon W. ;

Krosschell, Kristin ;

Arnold, W. David ;

Rutkove, Seward B. ;

Swoboda, Kathryn J. ;

Reyna, Sandra P. ;

Sakonju, Ai ;

Darras, Basil T. ;

Shell, Richard ;

Kuntz, Nancy ;

Castro, Diana ;

Iannaccone, Susan T. ;

Parsons, Julie ;

Connolly, Anne M. ;

Chiriboga, Claudia A. ;

McDonald, Craig ;

Burnette, W. Bryan ;

Werner, Klaus ;

Thangarajh, Mathula ;

Shieh, Perry B. ;

Finanger, Erika ;

Cudkowicz, Merit E. ;

McGovern, Michelle M. ;

McNeil, D. Elizabeth ;

Finkel, Richard ;

Kaye, Edward ;

Kingsley, Allison ;

Renusch, Samantha R. ;

McGovern, Vicki L. ;

Wang, Xueqian ;

Zaworski, Phillip G. ;

Prior, Thomas W. ;

Burghes, Arthur H. M. ;

Bartlett, Amy ;

Kissel, John T. .

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2016, 3 (02) :132-145

[14]

Spinal Muscular Atrophy [J].

Kolb, Stephen J. ;

Kissel, John T. .

NEUROLOGIC CLINICS, 2015, 33 (04) :831-+

[15]

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy [J].

Mendell, J. R. ;

Al-Zaidy, S. ;

Shell, R. ;

Arnold, W. D. ;

Rodino-Klapac, L. R. ;

Prior, T. W. ;

Lowes, L. ;

Alfano, L. ;

Berry, K. ;

Church, K. ;

Kissel, J. T. ;

Nagendran, S. ;

L'Italien, J. ;

Sproule, D. M. ;

Wells, C. ;

Cardenas, J. A. ;

Heitzer, M. D. ;

Kaspar, A. ;

Corcoran, S. ;

Braun, L. ;

Likhite, S. ;

Miranda, C. ;

Meyer, K. ;

Foust, K. D. ;

Burghes, A. H. M. ;

Kaspar, B. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (18) :1713-1722

[16]

Mendell J, 2018, NEUROLOGY, V90

[17]

Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care [J].

Mercuri, Eugenio ;

Finkel, Richard S. ;

Muntoni, Francesco ;

Wirth, Brunhilde ;

Montes, Jacqueline ;

Main, Marion ;

Mazzone, Elena S. ;

Vitale, Michael ;

Snyder, Brian ;

Quijano-Roy, Susana ;

Bertini, Enrico ;

Davis, Rebecca Hurst ;

Meyer, Oscar H. ;

Simonds, Anita K. ;

Schroth, Mary K. ;

Graham, Robert J. ;

Kirschner, Janbernd ;

Iannaccone, Susan T. ;

Crawford, Thomas O. ;

Woods, Simon ;

Qian, Ying ;

Sejersen, Thomas .

NEUROMUSCULAR DISORDERS, 2018, 28 (02) :103-115

[18]

Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B [J].

Miesbach, Wolfgang ;

Meijer, Karina ;

Coppens, Michiel ;

Kampmann, Peter ;

Klamroth, Robert ;

Schutgens, Roger ;

Tangelder, Marco ;

Castaman, Giancarlo ;

Schwaeble, Joachim ;

Bonig, Halvard ;

Seifried, Erhard ;

Cattaneo, Federica ;

Meyer, Christian ;

Leebeek, Frank W. G. .

BLOOD, 2018, 131 (09) :1022-1031

[19]

The changing natural history of spinal muscular atrophy type 1 [J].

Oskoui, M. ;

Levy, G. ;

Garland, C. J. ;

Gray, J. M. ;

O'Hagen, J. ;

De Vivo, D. C. ;

Kaufmann, P. .

NEUROLOGY, 2007, 69 (20) :1931-1936

[20]

Nusinersen demonstrates greater efficacy in infants with shorter disease duration: End of study results from the ENDEAR study in infants with spinal muscular atrophy (SMA) [J].

Servais, L. ;

Farrar, M. ;

Finkel, R. ;

Kirschner, J. ;

Muntoni, F. ;

Sun, P. ;

Gheuens, S. ;

Schneider, E. ;

Farwell, W. .

NEUROMUSCULAR DISORDERS, 2017, 27 :S211-S211

← 1 2 3 →